PetMeds® Files Form 10-K for Fiscal 2025
PetMeds (NASDAQ: PETS) filed its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
Key fiscal 2025 results: net sales $227.0 million (below prior preliminary range of $231.6–$233.6 million), net loss $6.3 million (wider than prior preliminary $4.5–$5.0 million), and cash $54.7 million with no debt. The company recorded a $1.2 million non-cash intangible impairment and restated promotional sales reimbursements from revenue to cost of sales, which the company says did not affect net income.
Management said it will file Form 10-Q for Q1 ended June 30, 2025 and subsequent quarterly filings "as soon as practicable" but gave no firm dates.
PetMeds (NASDAQ: PETS) ha depositato il proprio Rapporto Annuale sul modulo 10-K per l’esercizio chiuso al 31 marzo 2025.
Risultati chiave del 2025: fatturato netto di 227,0 milioni di dollari (inferiore all’intervallo preliminare precedente di 231,6–233,6 milioni), perdita netta di 6,3 milioni di dollari (più ampia del preliminare precedente di 4,5–5,0 milioni), e liquidità di cassa di 54,7 milioni di dollari con nessun debito. L’azienda ha registrato una svalutazione non monetaria di 1,2 milioni di dollari su attività immateriali e ha riclassificato i rimborsi promozionali sulle vendite dai ricavi ai costi di vendita, che l’azienda afferma non abbiano influenzato l’utile netto.
La dirigenza ha dichiarato che presenterà il Form 10-Q per il primo trimestre terminato il 30 giugno 2025 e i successivi rendiconti trimestrali “il prima possibile”, ma non ha fornito date precise.
PetMeds (NASDAQ: PETS) presentó su Informe Anual en el Formulario 10-K para el ejercicio fiscal que terminó el 31 de marzo de 2025.
Resultados clave de 2025: ventas netas de 227,0 millones de dólares (por debajo del rango preliminar anterior de 231,6–233,6 millones), pérdida neta de 6,3 millones de dólares (más amplia que el preliminar anterior de 4,5–5,0 millones), y efectivo de 54,7 millones de dólares con sin deuda. La empresa registró una pérdida por deterioro de activos intangibles no monetaria de 1,2 millones de dólares y reclasificó los reembolsos promocionales de ventas de ingresos a costo de ventas, lo que la empresa dice que no afectó al ingreso neto.
La dirección dijo que presentará el Formulario 10-Q para el Q1 terminado el 30 de junio de 2025 y presentaciones trimestrales posteriores “lo antes posible” pero no dio fechas firmes.
PetMeds (NASDAQ: PETS)가 2025년 3월 31일 종료된 회계연도에 대한 10-K 양식을 연차보고서로 제출했습니다.
주요 2025 회계연도 결과: 순매출 2억 2,700만 달러 (이전 예비 범위인 2억 3,160만~2억 3,360만 달러보다 낮음), 순손실 630만 달러 (이전 예비 450만~500만 달러보다 확대), 현금 5,470만 달러로 부채 없음. 회사는 비현금 무형자산 손상 120만 달러를 기록했고, 매출에서 홍보 판매 환급을 매출원가로 재분류했으며, 이는 순이익에 영향을 주지 않았다고 회사는 밝혔습니다.
경영진은 2025년 6월 30일 종료된 1분기 및 이후 분기 보고서를 가능한 한 빨리 제출하겠다고 밝혔지만 확정일은 제시하지 않았습니다.
PetMeds (NASDAQ: PETS) a déposé son rapport annuel sur le formulaire 10-K pour l’exercice clos le 31 mars 2025.
Résultats clés de 2025 : chiffre d’affaires net de 227,0 millions de dollars (en dessous de la fourchette préliminaire précédente de 231,6–233,6 millions), perte nette de 6,3 millions de dollars (plus élevée que le préliminaire précédent de 4,5–5,0 millions), et un fonds de roulement de 54,7 millions de dollars avec aucune dette. La société a enregistré une sous-performance non monétaire d’actifs incorporels de 1,2 million de dollars et a reclassé les remboursements promotionnels des ventes des revenus au coût des ventes, ce que la société affirme n’avoir impacté ni le résultat net.
La direction a déclaré qu’elle déposera le formulaire 10-Q pour le premier trimestre clos le 30 juin 2025 et les dépôts trimestriels suivants « dès que possible », mais n’a pas donné de dates précises.
PetMeds (NASDAQ: PETS) hat seinen Jahresbericht auf dem Formular 10-K für das Geschäftsjahr bis zum 31. März 2025 eingereicht.
Wesentliche Ergebnisse für 2025: Netto-Umsatz 227,0 Mio. USD (unter dem vorläufigen Bereich von 231,6–233,6 Mio. USD), Nettoverlust 6,3 Mio. USD (grösser als der vorhergehende vorläufige Bereich von 4,5–5,0 Mio. USD) und Barbestand 54,7 Mio. USD bei keiner Verschuldung. Das Unternehmen verzeichnete eine nicht zahlungsmäßige Abwertung immaterieller Vermögenswerte von 1,2 Mio. USD und hat die Rückerstattungen für Werbeaktionen von Umsatz zu Kosten der Verkäufe umklassifiziert, was das Unternehmen laut eigener Angabe nicht auf das Nettoeinkommen beeinflusst hat.
Das Management sagte, es werde das Form 10-Q für das am 30. Juni 2025 endende Q1 sowie nachfolgende Quartalsberichte „so bald wie möglich“ einreichen, gab jedoch kein festes Datum bekannt.
PetMeds (بورصة ناسداك: PETS) قدمت تقريرها السنوي على النموذج 10-K للسنة المالية المنتهية في 31 مارس 2025.
النتائج الأساسية لعام 2025: مبيعات صافية قدرها 227.0 مليون دولار (أقل من النطاق التمهيدي السابق البالغ 231.6–233.6 مليون دولار)، خسارة صافية قدرها 6.3 مليون دولار (أوسع من التقدير التمهيدي السابق 4.5–5.0 مليون دولار)، ونقدية 54.7 مليون دولار مع عدم وجود دين. سجلت الشركة إطفاء غير نقدي لأصول غير مادية بقيمة 1.2 مليون دولار وأعادت تصنيف تعويضات ترويجية من الإيرادات إلى تكاليف المبيعات، وهو ما تقول الشركة أنه لم يؤثر على صافي الدخل.
قالت الإدارة إنها ستقدم نموذج 10-Q للربع الأول المنتهي في 30 يونيو 2025 وبقيّة التقارير ربع السنوية «في أقرب وقت ممكن» لكنها لم تقدم تواريخ محددة.
PetMeds (NASDAQ: PETS) 已就截至 2025 年 3 月 31 日的财政年度提交了 Form 10-K 年度报告。
2025 年关键业绩：净销售额 2.270 亿美元（低于此前初步区间 2.316–2.336 亿美元），净亏损 630 万美元（高于此前初步 450–500 万美元），以及 现金 5470 万美元，无债务。公司记录了 非现金无形资产减值 120 万美元，并将 promotional 销售的退还从收入重新分类到销售成本，公司表示这并未影响净利润。
管理层表示将就截至 2025 年 6 月 30 日的 Q1 及随后的季度报披露表格 10-Q，并“在尽快的时间内”提交，但未给出具体日期。
- Cash balance of $54.7 million as of March 31, 2025
- No debt on the balance sheet as of March 31, 2025
- Form 10-K for fiscal 2025 filed, enabling resumption of SEC reporting
- Net sales of $227.0 million, below the preliminary range of $231.6–$233.6 million
- Net loss of $6.3 million, larger than prior estimate of $4.5–$5.0 million
- $1.2 million non-cash impairment charge for intangible assets
- Restatement moved promotional sales reimbursements from revenue to cost of sales
Insights
Form 10-K filed: revenue slightly below prior range, larger net loss driven by a non‑cash impairment; company has healthy cash and no debt.
PetMeds reported net sales of
Key dependencies and risks include completion of the resumed quarterly filings and the effectiveness of the disclosed internal process enhancements; the filing notes timelines are unspecified and Q1/Q2 filing dates are pending. The restatement and impairment are discrete, documented effects; they reduce clarity on underlying operating trends until upcoming quarterly reports provide sequential data.
Watch for the company to file its Form 10‑Q for the quarter ended
DELRAY BEACH, Fla., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today filed with the Securities and Exchange Commission (SEC) its Annual Report on Form 10-K for the fiscal year ended March 31, 2025.
Fiscal 2025 Financial Highlights
- Net sales of
$227.0 million for fiscal 2025, below the preliminary estimated range of$231.6 million to$233.6 million , primarily due to the previously announced restatement of promotional sales reimbursements from revenues to cost of sales, which had no impact on net income - Net loss of
$6.3 million , more than the previously announced preliminary estimated range of$4.5 million to$5.0 million , primarily due to the previously announced$1.2 million non-cash impairment charge for intangible assets - Cash of
$54.7 million as of March 31, 2025, and no debt
“We greatly appreciate the patience of our shareholders over the past several months,” said Board Chair and Interim CEO Leslie C. G. Campbell. “With our Form 10-K for fiscal 2025 now filed and actions taken to enhance our internal processes, we can now fully dedicate our efforts to operational execution and building a platform for long-term value creation. Most importantly we will continue to deliver to our customers the care they trust, which has been our legacy as a pioneer in the digital pharmacy industry for nearly 30 years. We now plan to file, as soon as practicable, our Quarterly Report on Form 10-Q for the first quarter ended June 30, 2025, followed by our earnings results and corresponding filings for the second quarter ended September 30, 2025, and thereby resume the normal quarterly reporting schedule. While we are unable at this time to determine exact dates for our Q1 and Q2 filings with the SEC or the related earnings announcements, we expect to resume our normal cadence of quarterly earnings calls promptly once our SEC filings are current.”
About PetMed Express, Inc.
Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness and the veterinarians who serve them. Through its PETS family of brands, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Company’s efforts to leverage its brand and legacy as a pioneer in the digital pet pharmacy industry for nearly 30 years, enhance its operational execution, and build a platform for long-term value creation, as well as statements regarding the anticipated timing for the filing of the Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 and the related earnings announcements. Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events, which are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors, including but not limited to, the results of the now completed investigation by the Audit Committee of the Company’s Board of Directors, the risk that the completion of the filing of the Company’s Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 may take longer than expected, and other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
Investor Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
investor@petmeds.com
FAQ
What did PetMeds (PETS) report for fiscal 2025 net sales and how did they compare to prior estimates?
Why did PetMeds (PETS) report a larger net loss in fiscal 2025?
What is PetMeds' (PETS) cash position and debt level as of March 31, 2025?
Has PetMeds (PETS) completed its Form 10-K and when will it file its next Form 10-Q?
What accounting change did PetMeds (PETS) disclose in the 10-K?
